Adverse effects of oral corticosteroids in relation to dose in patients with lung disease.
BACKGROUND
The adverse effects of oral corticosteroids are widely recognised but there are few quantitative data on which to base advice to patients. In a two part cross sectional study we compared adverse effects in patients with lung disease taking oral corticosteroids and control subjects and related the adverse effects to corticosteroid dose in the patient group.


METHODS
Data on oral corticosteroid use, lifestyle, fractures, and other possible adverse effects were collected by questionnaire and compared between a community based cohort of patients taking continuous or frequent intermittent oral corticosteroids for asthma, chronic obstructive pulmonary disease, or alveolitis and age and sex matched control subjects. Dose related effects were explored in the corticosteroid group using cumulative dose quartiles and multiple logistic regression.


RESULTS
A total of 367 patients (> or = 50 years, 48% female) and 734 control subjects completed the questionnaire. The cumulative incidence of fractures since the time of diagnosis was 23% for patients taking oral corticosteroids and 15% in the control group (odds ratio (OR) 1.8; 95% confidence interval (CI) 1.3 to 2.6). Patients were more likely to have had a fracture of the vertebrae (OR 10; 95% CI 2.9 to 34), hip (OR 6; 95% CI 1.2 to 30), and ribs or sternum (OR 3.2, 95% CI 1.6 to 6.6) than control subjects. They also reported a significant increase in cataracts, use of antacids, muscle weakness, back pain, bruising, oral candidiasis, and having fewer teeth. The effects of oral corticosteroids were dose related: the odds ratio for patients in the highest compared with the lowest cumulative dose quartile (median prednisolone dose 61 g versus 5 g) ranged from 2 for all fractures to 9 for vertebral fractures and bruising.


CONCLUSIONS
By quantifying the morbidity associated with the use of oral corticosteroids, this study should help to rationalise their long term use.
Division of Respiratory Medicine, City Hospital, Nottingham NG5 1PB, UK. lj_walsh@hotmail.com
L J
LJ
Walsh
C A
CA
Wong
J
J
Oborne
S
S
Cooper
S A
SA
Lewis
M
M
Pringle
R
R
Hubbard
A E
AE
Tattersfield
D000284:Administration, Oral; D000368:Aged; D001249:Asthma / Q000188:drug therapy; D003430:Cross-Sectional Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects*; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D016103:Spinal Fractures / Q000139:chemically induced
D005938:Glucocorticoids; D011239:Prednisolone